Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$26.51+0.60 (+2.32%)
Close on Nov 19, 2026Market cap $1.04BP/E –Yield –
Alto Neuroscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Alto Neuroscience's free cash flow for the twelve months ending Sep 30, 2026 was -$79.68M. For fiscal 2025 it was -$51.79M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$51.79M | – |
| FY2024 | Dec 31, 2024 | -$49.50M | – |
| FY2023 | Dec 31, 2023 | -$33.92M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.76M | – |
| Q2 FY2026 | Jun 30, 2026 | -$19.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.53M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.21M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.69M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.55M | – |
See a number that looks wrong?